Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.

about

SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis

P2860

Q58101254-5C8CBD22-4D07-4844-84BE-74E919985048 Q58695474-573046CA-6627-4B64-8B93-1BD21514372C

P2860

Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.

Item

http://www.wikidata.org/entity/Q39294871

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Palbociclib: A Review in HR-Po ...... d or Metastatic Breast Cancer.

@en

Palbociclib: A Review in HR-Po ...... d or Metastatic Breast Cancer.

@nl

type

Item

label

Palbociclib: A Review in HR-Po ...... d or Metastatic Breast Cancer.

@en

Palbociclib: A Review in HR-Po ...... d or Metastatic Breast Cancer.

@nl

prefLabel

Palbociclib: A Review in HR-Po ...... d or Metastatic Breast Cancer.

@en

Palbociclib: A Review in HR-Po ...... d or Metastatic Breast Cancer.

@nl

P1476

Palbociclib: A Review in HR-Po ...... d or Metastatic Breast Cancer.

@en

P2093

Esther S Kim

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Palbociclib and Letrozole in Advanced Breast Cancer.

P2888

s11523-017-0492-7

P304

373-383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-017-0492-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lesley J Scott

P577

2017-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28488183

http://www.w3.org/2001/XMLSchema#string

Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.

about

P2860

P2860

Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698